<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2019-12-3-30-36</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-299</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Клинико-инструментальные критерии риска метастазирования меланомы хориоидеи</article-title><trans-title-group xml:lang="en"><trans-title>Determining the risk of metastasis of choroidal melanoma: clinical and instrumental criteria</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Panova</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заместитель директора по научной работе</p><p>192283, Санкт-Петербург, ул. Ярослава Гашека, д. 21</p></bio><bio xml:lang="en"><p>Dr. Med. Sci., Professor, deputy director for science</p><p>21, Yaroslava Gasheka St., St. Petersburg, 192283</p></bio><email xlink:type="simple">eyeren@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasova</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-онколог, офтальмолог</p><p>454087, Челябинск, ул. Блюхера, д. 42</p></bio><bio xml:lang="en"><p>oncologist, ophthalmologist</p><p>42, Blyukhera St., Chelyabinsk, 454087</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гюнтнер</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gyuntner</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, заведующая онкологическим офтальмологическим отделением</p><p>454087, Челябинск, ул. Блюхера, д. 42</p></bio><bio xml:lang="en"><p>Cand. Med. Sci., head of department of oncological ophthalmology</p><p>42, Blyukhera St., Chelyabinsk, 454087</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самкович</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Samkovich</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-офтальмолог, младший научный сотрудник</p><p>192283, Санкт-Петербург, ул. Ярослава Гашека, д. 21</p></bio><bio xml:lang="en"><p>ophthalmologist, junior researcher of the scientific and educational department</p><p>21, Yaroslava Gasheka St., St. Petersburg, 192283</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шаманова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shamanova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, врач-патологоанатом; врач-офтальмолог</p><p>454087, Челябинск, ул. Блюхера, д. 42; 454080, Челябинск, пр. Ленина, д. 82</p></bio><bio xml:lang="en"><p>Cand. Med. Sci., pathologist; ophthalmologist</p><p>42, Blyukhera St., Chelyabinsk, 454087; 82, Prospekt Lenina, 454080, Chelyabinsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский филиал ФГАУ «НМИЦ МНТК “Микрохирургия глаза" им. акад. С.Н. Федорова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg branch of S.N. Fyodorov Eye Microsurgery Clinic</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chelyabinsk regional clinical centre for oncology and nuclear medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ «Челябинский областной клинический центр онкологии и ядерной медицины; МБУЗ «Городская клиническая больница № 2»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chelyabinsk regional clinical centre for oncology and nuclear medicine ;  City Clinical Hospital No 2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>08</month><year>2019</year></pub-date><volume>12</volume><issue>3</issue><fpage>30</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Панова И.Е., Власова О.С., Гюнтнер Е.И., Самкович Е.В., Шаманова А.Ю., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Панова И.Е., Власова О.С., Гюнтнер Е.И., Самкович Е.В., Шаманова А.Ю.</copyright-holder><copyright-holder xml:lang="en">Panova I.E., Vlasova O.S., Gyuntner E.I., Samkovich E.V., Shamanova A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/299">https://roj.igb.ru/jour/article/view/299</self-uri><abstract><p>Целью данного исследования явилось изучение частоты и клинико-инструментальных критериев риска метастазирования меланомы хориоидеи (МХ).</p><sec><title>Материал и методы</title><p>Материал и методы. Представлен детальный анализ клинического материала за период  2000–2018 гг., включающий 304 пациента с МХ, постоянно наблюдавшихся в условиях офтальмоонкологического центра многопрофильного онкологического учреждения.</p></sec><sec><title>Результаты</title><p> Результаты. Метастатическое поражение различных органов диагностировано у 66 (21,7 %) пациентов, средний возраст которых на момент верификации метастатического поражения составил 55,65 ± 13,4 года, в гендерном соотношении превалировали женщины (36 пациентов — 54,5 %). Метастазы в печень обнаружены у 63,6 %, в легкие — 4,5 %, множественные метастазы — у 31,9 % пациентов. При регулярном динамическом наблюдении критическим сроком выявления метастазов являлся интервал от 1 года до 5 лет — 77,2 % больных с метастатическим поражением и 16,8 % из общего числа пролеченных больных. Средние сроки метастазирования после ликвидационного лечения составили 27,75 ± 22,06 мес, при органосохранном — 61,57 ± 50,32 мес. Метастатический процесс диагностировался преимущественно при больших (63,6 %) и средних (28,8 %) МХ. Установлены критерии риска развития метастазов при МХ: мужской пол, преэкваториальная локализация, грибовидная форма, большие размеры, пигментированная опухоль, транссудативная отслойка сетчатки, смешанный патогистологический вариант опухоли.</p></sec><sec><title>Заключение</title><p>Заключение. Установленные клинико-инструментальные критерии риска развития метастатического поражения при МХ следует учитывать при планировании диспансерного наблюдения за данной группой больных. </p></sec></abstract><trans-abstract xml:lang="en"><p>The purpose was to study the prevalence of metastasis of choroidal melanoma (CM) and clinical and instrumental criteria of the risk of such metastasis.</p><sec><title>Material and methods</title><p>Material and methods. A detailed analysis of clinical material for the period of 2000–2018 is presented, involving 304 patients with CM under continuous observation by an ophthalmic oncology center of a multidisciplinary cancer institution.</p></sec><sec><title>Results</title><p> Results. Metastatic lesion of various organs was diagnosed in 66 (21.7 %) patients. The average age of patients at the time of metastatic lesion verification was 55.65 ± 13.4 years, with the number of women patients prevailing (36 patients out of 66, or 54.5 %). Liver metastases were found in 63.6 %, lungs metastases, 4.5 %, multiple metastases — 31.9 % of patients. With regular follow-up, the critical period for metastasis detection was between one to five years — 77.2 % of patients with metastatic lesions and 16.8 % of the total number of the treated patients. The average time of metastasis appearance after the liquidation treatment was 27.75 ± 22.06 months, in cases of organ preservation treatment it was 61.57 ± 50.32 months. A metastatic process was diagnosed predominantly in large (63.6 %) and medium (28.8 %) CM. The risk criteria for metastatic development in CM were found to be: male gender, pre-equatorial localization, fungoid shape, large tumor size, pigmented tumor, transudative retinal detachment, mixed histopathological tumor variant.</p></sec><sec><title>Conclusion</title><p>Conclusion. The established clinical and instrumental criteria of the risk of metastatic lesion in choroidal melanoma should be considered when planning follow-up monitoring of this group of patients. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома хориоидеи</kwd><kwd>метастатическая болезнь</kwd><kwd>лечение меланомы хориоидеи</kwd><kwd>метастазы меланомы хориоидеи</kwd><kwd>критерии метастазирования</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>choroidal melanoma</kwd><kwd>metastatic disease</kwd><kwd>treatment of choroidal melanoma</kwd><kwd>choroidal melanoma metastases</kwd><kwd>metastasis criteria</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф. Офтальмоонкология. Руководство для врачей. Москва: Медицина; 2002.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F. Ophthalmooncology. Guidelines for physicians. Moscow: Meditsina; 2002 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Важенин А.В., Панова И.Е. Избранные вопросы онкоофтальмологии. Москва: РАМН; 2006.</mixed-citation><mixed-citation xml:lang="en">Vazhenin A.V., Panova I.E. Selected issues of oncoophthalmology Moscow: RAMN; 2006 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shields C.L., Kaliki S., Furuta M., Mashayekhi A., Shields J.A. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012; 32 (7): 1363–72. doi: 10.1097/IAE.0b013e31824d09a8</mixed-citation><mixed-citation xml:lang="en">Shields C.L., Kaliki S., Furuta M., Mashayekhi A., Shields J.A. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012; 32 (7): 1363–72. doi: 10.1097/IAE.0b013e31824d09a8</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф., Панова И.Е., Саакян С.В. Офтальмоонкология: новое за последние два десятилетия. Вестник офтальмологии. 2014; 130 (6): 13–9.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F., Panova I.E., Saakyan S.V. Ophthalmooncology: new over the past two decades. Vestnik oftal'mologii. 2014; 130 (6): 13–9 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Саакян С.В., Ширина Т.В. Анализ метастазирования и выживаемости больных увеальной меланомой. Опухоли головы и шеи. 2012; 2: 53–6.</mixed-citation><mixed-citation xml:lang="en">Saakyan S.V., Shirina T.V. Analysis of metastasis and survival of patients with uveal melanoma. Opukholi golovy i shei. 2012; 2: 53–6 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Beran T.M., McCannel T.A., Stanton A.L., Straatsma B.R., Burgess B.L. Reactions to and desire for prognostic testing in choroidal melanoma patients. J. Genetic counseling. 2009; 18 (3): 265–74.</mixed-citation><mixed-citation xml:lang="en">Beran T.M., McCannel T.A., Stanton A.L., Straatsma B.R., Burgess B.L. Reactions to and desire for prognostic testing in choroidal melanoma patients. J. Genetic counseling. 2009; 18 (3): 265–74.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bandarchi B., Ma L., Navab R., Seth A., Rasty G. From melanocyte to metastatic malignant melanoma. Dermatol. Res. Pract. 2010; 2010. pii: 583748. doi: 10.1155/2010/583748</mixed-citation><mixed-citation xml:lang="en">Bandarchi B., Ma L., Navab R., Seth A., Rasty G. From melanocyte to metastatic malignant melanoma. Dermatol. Res. Pract. 2010; 2010. pii: 583748. doi: 10.1155/2010/583748</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф., Вaльский В.В., Зарубей Г.Д. Метастатическое поражение печени у больных с увеальной меланомой. Вестник офтальмологии. 1998; 1 (21): 21–3.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F., Val'skiy V.V., Zarubey G.D. Metastatic liver damage in patients with uveal melanoma. Vestnik oftal'mologii. 1998; 1 (21): 21–3 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Damato B.E., Heimann H., Kalirai H., Coupland S.E. Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA ophthalmology. 2014; 132 (5): 605–13. doi:10.1001/ jamaophthalmol.2014.77</mixed-citation><mixed-citation xml:lang="en">Damato B.E., Heimann H., Kalirai H., Coupland S.E. Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA ophthalmology. 2014; 132 (5): 605–13. doi:10.1001/ jamaophthalmol.2014.77</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Damato B., Eleuteri A., Taktak A.F., Coupland S.E. Estimating prognosis for survival after treatment of choroidal melanoma. Progress in retinal and eye research. 2011; 30 (5): 285–95. https:// doi.org/10.1016/j.preteyeres.2011.05.003</mixed-citation><mixed-citation xml:lang="en">Damato B., Eleuteri A., Taktak A.F., Coupland S.E. Estimating prognosis for survival after treatment of choroidal melanoma. Progress in retinal and eye research. 2011; 30 (5): 285–95. https:// doi.org/10.1016/j.preteyeres.2011.05.003</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zakka K.A., Foos R.Y., Omphroy C.A., Straatsma B.R. Malignant melanoma. Analysis of an autopsy population. Ophthalmology. 1980; 87 (549): 56–8.</mixed-citation><mixed-citation xml:lang="en">Zakka K.A., Foos R.Y., Omphroy C.A., Straatsma B.R. Malignant melanoma. Analysis of an autopsy population. Ophthalmology. 1980; 87 (549): 56–8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shields J.A., Shields C.L. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology. 2015; 122 (2): 414–28. https://doi.org/10.1016/j. ophtha.2014.08.046</mixed-citation><mixed-citation xml:lang="en">Shields J.A., Shields C.L. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology. 2015; 122 (2): 414–28. https://doi.org/10.1016/j. ophtha.2014.08.046</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shields C.L., Ganguly A., Bianciotto C.G., et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011; 118 (2): 396401. https://doi.org/10.1016/j.ophtha.2010.05.023</mixed-citation><mixed-citation xml:lang="en">Shields C.L., Ganguly A., Bianciotto C.G., et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011; 118 (2): 396401. https://doi.org/10.1016/j.ophtha.2010.05.023</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Саакян С.В., Цыганков А.Ю., Амирян А.Г., Склярова Н.В., Залетаев Д.В. Выживаемость при увеальной меланоме: роль молекулярно-генетических факторов. Вестник офтальмологии. 2016; 132 (1): 3–9. doi:10.17116/oftalma201613213-9</mixed-citation><mixed-citation xml:lang="en">Saakyan S.V., Tsygankov A.Yu., Amiryan A.G., Sklyarova N.V., Zaletaev D.V. Survival in uveal melanoma: the role of molecular genetic factors. Vestnik oftal'mologii. 2016; 132 (1): 3–9 (in Russian). doi:10.17116/oftalma201613213-9</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881–5. https://doi.org/10.1016/j.ophtha.2011.01.040</mixed-citation><mixed-citation xml:lang="en">Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881–5. https://doi.org/10.1016/j.ophtha.2011.01.040</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shields J.A. Diagnosis and management of intraocular tumors. St. Louis. CV Mosby. 1983: 279–321.</mixed-citation><mixed-citation xml:lang="en">Shields J.A. Diagnosis and management of intraocular tumors. St. Louis. CV Mosby. 1983: 279–321.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Собин Л.Х., Господарович М.К., Виттекинд К. TNM. Классификация злокачественных опухолей. Available at: https://www. logobook.ru/prod_show.php?object_uid=14096613</mixed-citation><mixed-citation xml:lang="en">Sobin L.H., Gospodarowicz M.K., Wittekind K. TNM. Classification of malignant tumors. (in Russian) Available at: https://www. logobook.ru/prod_show.php?object_uid=14096613</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Willson J.K., Albert D. M., Diener-West M., ,et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. Arch. Ophthalmol. 2001; 119 (5): 670–6.</mixed-citation><mixed-citation xml:lang="en">Willson J.K., Albert D. M., Diener-West M., ,et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15. Arch. Ophthalmol. 2001; 119 (5): 670–6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Зиангирова Г.Г., Лихванцева В.Г. Опухоли сосудистого тракта глаза. Москва: Последнее слово; 2003.</mixed-citation><mixed-citation xml:lang="en">Ziangirova G.G., Likhvantseva V.G. Tumors of the vascular tract of the eye. Moscow: Poslednee slovo; 2003 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ewing J. Metastasis. In: Neoplastic diseases: A Treatise on Tumours. Ed. J. Ewing. Philadelphia: W.B. Saunders; 1940: 62–74.</mixed-citation><mixed-citation xml:lang="en">Ewing J. Metastasis. In: Neoplastic diseases: A Treatise on Tumours. Ed. J. Ewing. Philadelphia: W.B. Saunders; 1940: 62–74.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dithmar S., Diaz C.E., Grossniklaus H.E. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina (Philadelphia, Pa.). 2000; 20 (1): 76–9. doi: 10.1097/00006982200001000-00014</mixed-citation><mixed-citation xml:lang="en">Dithmar S., Diaz C.E., Grossniklaus H.E. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina (Philadelphia, Pa.). 2000; 20 (1): 76–9. doi: 10.1097/00006982200001000-00014</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989; 8 (2): 98–101.</mixed-citation><mixed-citation xml:lang="en">Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989; 8 (2): 98–101.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Fidler I.J., Yano S., Zhang R.D., et al. The seed and soil hypothesis; vascularization and brain metastases. Lancet Oncol. 2002; 3 (1): 53–7. https://doi.org/10.1016/S1470-2045(01)00622-2</mixed-citation><mixed-citation xml:lang="en">Fidler I.J., Yano S., Zhang R.D., et al. The seed and soil hypothesis; vascularization and brain metastases. Lancet Oncol. 2002; 3 (1): 53–7. https://doi.org/10.1016/S1470-2045(01)00622-2</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker E.V. Cancer metastasis: a product of tumor-host interactions. Curr. Probl. Cancer. 1979; 3 (7): 1–59.</mixed-citation><mixed-citation xml:lang="en">Sugarbaker E.V. Cancer metastasis: a product of tumor-host interactions. Curr. Probl. Cancer. 1979; 3 (7): 1–59.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Damato B. The managеment of uveal melanoma in the next millennium. Ophthalmology Clinics of North America. 1999; 12 (4): 493–505.</mixed-citation><mixed-citation xml:lang="en">Damato B. The managеment of uveal melanoma in the next millennium. Ophthalmology Clinics of North America. 1999; 12 (4): 493–505.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Singh A.D., Rennie I.G., Kivela T., et al. The Zimmerman−McLean− Foster hypothesis: 25 years later. Br. J. Ophthalmol. 2004; 88 (6): 962–7. http://dx.doi.org/10.1136/bjo.2003.029058</mixed-citation><mixed-citation xml:lang="en">Singh A.D., Rennie I.G., Kivela T., et al. The Zimmerman−McLean− Foster hypothesis: 25 years later. Br. J. Ophthalmol. 2004; 88 (6): 962–7. http://dx.doi.org/10.1136/bjo.2003.029058</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф., Вальский В.В., Гусев Г.А., Пантелеева О.Г., Юровская Н.Н. Риск метастазирования меланом хориоидеи после брахитерапии. Вестник офтальмологии. 2003; 2: 26–8.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F., Val'skiy V.V., Gusev G.A., Panteleeva O.G., Yurovskaya N.N. Risk of choroidal melanoma metastasis after brachytherapy. Vestnik oftal'mologii. 2003; 2: 26–8 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Augsburger J.J., Correa Z.M., Freire J., Brady L.W. Longterm survival choroidal and ciliary body melanoma after enucleation versus plaque radiotherapy. Ophthalmology. 1998; 105:1670−8.</mixed-citation><mixed-citation xml:lang="en">Augsburger J.J., Correa Z.M., Freire J., Brady L.W. Longterm survival choroidal and ciliary body melanoma after enucleation versus plaque radiotherapy. Ophthalmology. 1998; 105:1670−8.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zakka K.A., Foos R.Y., Omphroy C.A., Straatsma B.R. Malignant melanoma. Analysis of an autopsy population. Ophthalmology. 1980; 87: 549–56.</mixed-citation><mixed-citation xml:lang="en">Zakka K.A., Foos R.Y., Omphroy C.A., Straatsma B.R. Malignant melanoma. Analysis of an autopsy population. Ophthalmology. 1980; 87: 549–56.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф. Современные аспекты лечения меланом хориоидеи: проблемы, дискуссионные вопросы. Вестник офтальмологии. 2006; 1 (13): 5–8.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F. Modern aspects of the treatment of melanoma of the choroid: problems, debatable questions. Vestnik oftal'mologii. 2006; 1 (13): 5–8 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф., Стоюхина А.С., Чесалин И.П. Брахитерапия меланом хориоидеи и вторичная энуклеация. Офтальмологические ведомости. 2014; 7 (2): 69–77.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F., Stoyukhina A.S., Chesalin I.P. Brachytherapy with choroidal melanomas and secondary enucleation. Oftal'mologicheskie vedomosti. 2014; 7 (2): 69–77 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Schuster R., Bechrakis N. E., Stroux A., Busse A. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 2011; 80 (1–2): 57–62. https://doi.org/10.1159/000328283</mixed-citation><mixed-citation xml:lang="en">Schuster R., Bechrakis N. E., Stroux A., Busse A. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 2011; 80 (1–2): 57–62. https://doi.org/10.1159/000328283</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Torres V., Triozzi P., Eng C., et al. Circulating tumor cells in uveal melanoma. Future Oncology. 2011; 7 (1): 101–9. https://doi. org/10.2217/fon.10.143</mixed-citation><mixed-citation xml:lang="en">Torres V., Triozzi P., Eng C., et al. Circulating tumor cells in uveal melanoma. Future Oncology. 2011; 7 (1): 101–9. https://doi. org/10.2217/fon.10.143</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Follmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self renew. Breast Cancer Res. 2008; 140: 62–73. https://doi.org/10.1186/bcr1982</mixed-citation><mixed-citation xml:lang="en">Follmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self renew. Breast Cancer Res. 2008; 140: 62–73. https://doi.org/10.1186/bcr1982</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ulmer A., Beutel J., Susskind D., et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clinical Cancer Research. 2008; 14 (14): 4469–74. doi: 10.1158/1078-0432.CCR-08-0012</mixed-citation><mixed-citation xml:lang="en">Ulmer A., Beutel J., Susskind D., et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clinical Cancer Research. 2008; 14 (14): 4469–74. doi: 10.1158/1078-0432.CCR-08-0012</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Suesskind D., Ulmer A., Schiebel U., et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmologica. 2011; 89 (1): 17–24. https:// doi.org/10.1111/j.1755-3768.2009.01617.x</mixed-citation><mixed-citation xml:lang="en">Suesskind D., Ulmer A., Schiebel U., et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmologica. 2011; 89 (1): 17–24. https:// doi.org/10.1111/j.1755-3768.2009.01617.x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
